Last Updated : July 24, 2024
Details
Generic Name:
talazoparib
Project Status:
Not filed
Therapeutic Area:
Breast Cancer
Manufacturer:
Pfizer Canada Inc.
Brand Name:
Talzenna
Project Line:
Reimbursement Review
Project Number:
NS0017-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
Monotherapy for the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curative radiation or surgery) or metastatic breast cancer, who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting, unless patients were inappropriate for these treatments.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024